Identification

Name
Oxazepam
Accession Number
DB00842  (APRD01152)
Type
Small Molecule
Groups
Approved
Description

Oxazepam is an intermediate-acting benzodiazepine used to treat alcohol withdrawal and anxiety disorders. Oxazepam is also the metabolite of other benzodiazpines.

Structure
Thumb
Synonyms
  • (+-)-Oxazepam
  • (RS)-Oxazepam
External IDs
J3.308A / NSC-169448 / WY-3498
Product Ingredients
IngredientUNIICASInChI Key
Oxazepam acetate611V4315UA1824-74-4FYRWUTOZBRWYCS-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bio-oxazepamTablet30 mgOralBiomed Pharma2003-04-23Not applicableCanada
Bio-oxazepamTablet15 mgOralBiomed Pharma2003-04-23Not applicableCanada
Bio-oxazepamTablet10 mgOralBiomed Pharma2003-04-23Not applicableCanada
Novoxapam Tab 10mgTablet10 mgOralNovopharm Limited1982-12-312015-10-26Canada
Novoxapam Tab 15mgTablet15 mgOralNovopharm Limited1982-12-312015-10-26Canada
Novoxapam Tab 30mgTablet30 mgOralNovopharm Limited1982-12-312015-10-26Canada
Oxazepam 10 Tab 10mgTablet10 mgOralPro Doc Limitee1980-12-31Not applicableCanada
Oxazepam 10mg TabletsTablet10 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Oxazepam 15 Tab 15mgTablet15 mgOralPro Doc Limitee1980-12-31Not applicableCanada
Oxazepam 15mg TabletsTablet15 mgOralLaboratoires Confab IncNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Oxazepam Tab 10mgTablet10 mgOralApotex Corporation1979-12-31Not applicableCanada
Apo Oxazepam Tab 15mgTablet15 mgOralApotex Corporation1979-12-31Not applicableCanada
Apo Oxazepam Tab 30mgTablet30 mgOralApotex Corporation1979-12-31Not applicableCanada
OxazepamCapsule, gelatin coated30 mg/1OralAphena Pharma Solutions Tennessee, Inc.2007-01-02Not applicableUs
OxazepamCapsule, gelatin coated10 mg/1OralActavis Pharma Company2007-01-02Not applicableUs00228 2067 10 nlmimage10 c11b60fb
OxazepamCapsule10 mg/1OralAphena Pharma Solutions Tennessee, Inc.1988-04-19Not applicableUs
OxazepamCapsule, gelatin coated10 mg/1OralAmerincan Health Packaging2007-07-31Not applicableUs
OxazepamCapsule15 mg/1OralRemedy Repack2016-09-30Not applicableUs
OxazepamCapsule, gelatin coated10 mg/1OralAphena Pharma Solutions Tennessee, Inc.2007-01-02Not applicableUs
OxazepamCapsule10 mg/1OralSandoz1988-04-192019-08-31Us
International/Other Brands
Adumbran / Alepam / Alopam / Anxiolit / Durazepam / Limbial / Medopam / Murelax / Noripam / Opamox / Ox-Pam / Oxascand / Praxiten / Purata / Serax (Landsteiner (Mexico)) / Serenal / Serenid / Serepax / Seresta / Serpax / Sobril / Tazepam / Vaben / Zaxpam
Categories
UNII
6GOW6DWN2A
CAS number
604-75-1
Weight
Average: 286.713
Monoisotopic: 286.050905313
Chemical Formula
C15H11ClN2O2
InChI Key
ADIMAYPTOBDMTL-UHFFFAOYSA-N
InChI
InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)
IUPAC Name
7-chloro-3-hydroxy-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
OC1N=C(C2=CC=CC=C2)C2=C(NC1=O)C=CC(Cl)=C2

Pharmacology

Indication

For the treatment of anxiety disorders and alcohol withdrawal.

Structured Indications
Pharmacodynamics

Oxazepam is believed to stimulate GABA receptors in the ascending reticular activating system. Since GABA is inhibitory, receptor stimulation increases inhibition and blocks both cortical and limbic arousal following stimulation of the brain stem reticular formation.

Mechanism of action

Similar to other benzodiazepines, oxazepam exerts its anxiolytic effects by potentiating the effect of gamma-aminobutyric acid (GABA) on GABA-A receptors through a cooperative mechanism of action. GABA receptors are ionotropic chloride-linked channel receptors that produce inhibitory postsynaptic potentials. When activated by GABA, the GABA receptor/chloride ionophore complex undergoes a conformational change that allows the passage of chloride ions through the channel. Benzodiazepines are believed to exert their effect by increasing the effect of GABA at its receptor. Benzodiazepine binding increases chloride conductance in the presence of GABA by increasing the frequency at which the channel opens. In contrast, barbiturates increase chloride conductance in the presence of GABA by prolonging the time in which the channel remains open. There are 18 subtypes of the GABA receptor subunits. The α2 subunit of the α2β3γ2 receptor complex is thought to mediate anxiolytic effects while the α1 subunit of the α1β2γ2 receptor complex is thought to mediate sedative, anticonvulsant and anterograde amnesia effects.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-4
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-5
potentiator
Human
AGamma-aminobutyric acid receptor subunit alpha-6
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit beta-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit gamma-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit delta
potentiator
Human
AGamma-aminobutyric acid receptor subunit epsilon
potentiator
Human
AGamma-aminobutyric acid receptor subunit pi
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-1
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-2
potentiator
Human
AGamma-aminobutyric acid receptor subunit rho-3
potentiator
Human
AGamma-aminobutyric acid receptor subunit theta
potentiator
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption

Well absorbed from the gastrointestinal tract following oral administration however is absorbed at a slower rate compared to other benzodiazepines like diazepam or flurazepam. Time to peak concentration = 2-4 hours. Onset of action is slow, > 3 hours, following oral administration.

Volume of distribution
Not Available
Protein binding

80-99%

Metabolism

No active metabolites. It is hepatically metabolized and undergoes glucuronidation. The glucuronidation of the S-isomer is catalyzed by UGT2B15. The glucuronidation of the R-isomer is catalyzed by UGT2B7 and UGT1A9.

Route of elimination

This product has a single, major inactive metabolite in man, a glucuronide excreted in the urine.

Half life

Mean elimination half-life - 8.2 hours (range of 5.7 to 10.9 hours)

Clearance
Not Available
Toxicity

Symptoms of overdose include confusion, drowsiness, and lethargy.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Oxazepam.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Oxazepam.Approved, Illicit, Investigational
Ambroxol acefyllinateThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Ambroxol acefyllinate.Experimental, Investigational
AminophyllineThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Aminophylline.Approved
AmiodaroneThe metabolism of Oxazepam can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Amperozide.Experimental
AprepitantThe serum concentration of Oxazepam can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with Aripiprazole.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Asenapine.Approved
AtazanavirThe metabolism of Oxazepam can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Oxazepam can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Azaperone.Investigational, Vet Approved
AzelastineOxazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Oxazepam is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Oxazepam is combined with Benzyl alcohol.Approved
BoceprevirThe metabolism of Oxazepam can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Oxazepam can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Oxazepam can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
BromazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Bupivacaine.Approved, Investigational
BuprenorphineOxazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Oxazepam.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Oxazepam.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Oxazepam.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Oxazepam is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Oxazepam can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Carisoprodol.Approved
CeritinibThe serum concentration of Oxazepam can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Oxazepam.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Oxazepam.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Oxazepam is combined with Citalopram.Approved
ClarithromycinThe metabolism of Oxazepam can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Oxazepam can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Oxazepam.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Oxazepam can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Clozapine.Approved
CobicistatThe metabolism of Oxazepam can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Oxazepam.Approved, Illicit
ConivaptanThe serum concentration of Oxazepam can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Oxazepam can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclobenzaprine.Approved
CyclosporineThe metabolism of Oxazepam can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Oxazepam can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Oxazepam can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Oxazepam can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Oxazepam can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Oxazepam can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Oxazepam.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Oxazepam is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Oxazepam can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Oxazepam can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Doxepin.Approved
DoxycyclineThe metabolism of Oxazepam can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Oxazepam is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved, Illicit
DronedaroneThe metabolism of Oxazepam can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Dyclonine.Approved
DyphyllineThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Dyphylline.Approved
EcgonineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Oxazepam is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Oxazepam is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Oxazepam can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Oxazepam can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Oxazepam.Approved
EthanolOxazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Oxazepam.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Oxazepam can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Oxazepam.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Oxazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Oxazepam can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Oxazepam can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Oxazepam can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Oxazepam.Approved
FospropofolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Oxazepam can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Oxazepam is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxazepam.Approved
HalothaneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Hyaluronidase.Approved, Investigational
HydrocodoneOxazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Oxazepam.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
IdelalisibThe serum concentration of Oxazepam can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Iloperidone.Approved
ImatinibThe metabolism of Oxazepam can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Oxazepam can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Indiplon.Investigational
IsavuconazoniumThe metabolism of Oxazepam can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Oxazepam.Approved, Vet Approved
IsradipineThe metabolism of Oxazepam can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Oxazepam can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Oxazepam can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Oxazepam can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Levorphanol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lidocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lofentanil.Illicit
LopinavirThe metabolism of Oxazepam can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Oxazepam.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lormetazepam.Approved
LovastatinThe metabolism of Oxazepam can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Oxazepam.Approved
LuliconazoleThe serum concentration of Oxazepam can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Oxazepam can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Oxazepam is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Oxazepam.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Metaxalone.Approved
MethadoneOxazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxazepam.Approved
MethotrimeprazineOxazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methylphenobarbital.Approved
MetyrosineOxazepam may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Oxazepam.Approved, Illicit
MifepristoneThe serum concentration of Oxazepam can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Oxazepam is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved, Investigational
MirtazapineOxazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Oxazepam can be decreased when it is combined with Mitotane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Oxazepam.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nalbuphine.Approved
NefazodoneThe metabolism of Oxazepam can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Oxazepam can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Oxazepam can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Oxazepam can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Oxazepam can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nitrazepam.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nitrous oxide.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Oxazepam.Approved, Investigational
OlaparibThe metabolism of Oxazepam can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Oxazepam is combined with Opium.Approved, Illicit
OrphenadrineOxazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Oxazepam is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Oxazepam can be increased when it is combined with Osimertinib.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Oxazepam.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Oxymorphone.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Oxazepam can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paliperidone.Approved
ParaldehydeOxazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Oxazepam.Approved, Vet Approved
PentobarbitalThe metabolism of Oxazepam can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
PerazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Oxazepam.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Oxazepam is combined with Phenibut.Experimental
PhenobarbitalThe metabolism of Oxazepam can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Phenoxyethanol.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Oxazepam.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Oxazepam can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleOxazepam may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Oxazepam.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Prilocaine.Approved
PrimidoneThe metabolism of Oxazepam can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxazepam.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Oxazepam.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Oxazepam is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Oxazepam.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Oxazepam is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quetiapine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Oxazepam can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Oxazepam is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Oxazepam.Approved, Investigational
RifabutinThe metabolism of Oxazepam can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Oxazepam can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Oxazepam can be increased when combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Oxazepam.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ritanserin.Investigational
RitonavirThe metabolism of Oxazepam can be decreased when combined with Ritonavir.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Romifidine.Vet Approved
RopiniroleOxazepam may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ropivacaine.Approved
RotigotineOxazepam may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Oxazepam.Approved
SaquinavirThe metabolism of Oxazepam can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Oxazepam.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Oxazepam can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Oxazepam can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Oxazepam can be increased when it is combined with Simeprevir.Approved
St. John's WortThe serum concentration of Oxazepam can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Oxazepam can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam.Approved, Investigational
SulfisoxazoleThe metabolism of Oxazepam can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sultopride.Experimental
SuvorexantOxazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tasimelteon.Approved
TeduglutideThe serum concentration of Oxazepam can be increased when it is combined with Teduglutide.Approved
TelaprevirThe metabolism of Oxazepam can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Oxazepam can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Oxazepam.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tetrodotoxin.Investigational
ThalidomideOxazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Oxazepam.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Oxazepam can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Oxazepam can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Oxazepam.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triazolam.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Oxazepam is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Oxazepam.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Oxazepam is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe metabolism of Oxazepam can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Veralipride.Experimental
VerapamilThe metabolism of Oxazepam can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Oxazepam can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Oxazepam can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Oxazepam can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zolazepam.Vet Approved
ZolpidemOxazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Oxazepam is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

References

General References
  1. Peppers MP: Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996 Jan-Feb;16(1):49-57. [PubMed:8700792]
  2. Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. [PubMed:6135616]
  3. Oelschlager H: [Chemical and pharmacologic aspects of benzodiazepines]. Schweiz Rundsch Med Prax. 1989 Jul 4;78(27-28):766-72. [PubMed:2570451]
  4. Christensen P, Lolk A, Gram LF, Kragh-Sorensen P: Benzodiazepine-induced sedation and cortisol suppression. A placebo-controlled comparison of oxazepam and nitrazepam in healthy male volunteers. Psychopharmacology (Berl). 1992;106(4):511-6. [PubMed:1349754]
  5. Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine]. Arch Fr Pediatr. 1977 Jan;34(1):74-89. [PubMed:851373]
  6. Altamura AC, Moliterno D, Paletta S, Maffini M, Mauri MC, Bareggi S: Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):423-40. doi: 10.1517/17425255.2013.759209. Epub 2013 Jan 21. [PubMed:23330992]
External Links
Human Metabolome Database
HMDB61121
KEGG Drug
D00464
KEGG Compound
C07359
PubChem Compound
4616
PubChem Substance
46506031
ChemSpider
4455
BindingDB
85031
ChEBI
7823
ChEMBL
CHEMBL568
Therapeutic Targets Database
DAP000243
PharmGKB
PA450731
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Oxazepam
ATC Codes
N05BA04 — Oxazepam
AHFS Codes
  • 28:24.08 — Benzodiazepines
FDA label
Download (356 KB)
MSDS
Download (44.2 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCocaine Use Disorders1
1CompletedTreatmentCocaine Use Disorders / Tobacco Use Disorders1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedTreatmentAlcohol Dependence / Alcohol Withdrawal Syndrome(AWS)1
Not AvailableCompletedTreatmentDependence, Cocaine1

Pharmacoeconomics

Manufacturers
  • Actavis elizabeth llc
  • American therapeutics inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
  • Alpharma us pharmaceuticals division
  • Quantum pharmics ltd
  • Parke davis div warner lambert co
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
TabletOral15 mg
TabletOral30 mg
CapsuleOral10 mg/1
CapsuleOral15 mg/1
CapsuleOral30 mg/1
Capsule, gelatin coatedOral10 mg/1
Capsule, gelatin coatedOral15 mg/1
Capsule, gelatin coatedOral30 mg/1
Prices
Unit descriptionCostUnit
Oxazepam 30 mg capsule1.2USD capsule
Serax 10 mg capsule1.17USD capsule
Oxazepam 15 mg capsule0.73USD capsule
Oxazepam 10 mg capsule0.6USD capsule
Apo-Oxazepam 30 mg Tablet0.09USD tablet
Apo-Oxazepam 15 mg Tablet0.07USD tablet
Apo-Oxazepam 10 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)205-206 °CPhysProp
water solubility179 mg/LNot Available
logP2.24HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0881 mg/mLALOGPS
logP2.01ALOGPS
logP2.92ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)10.61ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area61.69 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity77.89 m3·mol-1ChemAxon
Polarizability28.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9826
Blood Brain Barrier+0.9641
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.517
P-glycoprotein inhibitor INon-inhibitor0.8866
P-glycoprotein inhibitor IINon-inhibitor0.9167
Renal organic cation transporterNon-inhibitor0.8812
CYP450 2C9 substrateNon-substrate0.7692
CYP450 2D6 substrateNon-substrate0.8685
CYP450 3A4 substrateSubstrate0.5631
CYP450 1A2 substrateInhibitor0.8262
CYP450 2C9 inhibitorNon-inhibitor0.5063
CYP450 2D6 inhibitorNon-inhibitor0.8445
CYP450 2C19 inhibitorInhibitor0.5065
CYP450 3A4 inhibitorNon-inhibitor0.6563
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6407
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.7711
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.8229 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.999
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0699-7490000000-e90f4b8174c78110a07a
GC-MS Spectrum - EI-BGC-MSsplash10-0pxr-6490000000-98a9035e85eeea7c02e5
Mass Spectrum (Electron Ionization)MSsplash10-05r0-5590000000-87245820addec0215473
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0090000000-dc62fcc1bbffbe41a418
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-0babffe4ebd04774afee
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-93028caba51f80d16e67
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0490000000-e36258d846328fd12f7d
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0900000000-d4bd0b0355dc42f3606f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-cb90c6162b5e9a189120
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-000i-0090000000-cfdd9662d1f355ecf572
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-052f-0090000000-1c26508a42811abbe1cb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udl-0980000000-870c5260836b760916d2
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0090000000-f0561f08464034626ee2
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0090000000-d55c5dfc5658fa7a4e05
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0090000000-7682f5c8dc13b49aa59e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-526eef46646595e92a99
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-21ba02c0de7b6e8c51ff
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014r-0090000000-61c68689382573975141
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0090000000-74e04f10a2b801bba9ba
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0490000000-31f82dff12f0e9088719
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f6x-0960000000-90758cc09aa77510b07c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0w2c-1920000000-c885875f53b407082d2c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0090000000-ff519596d2f3661430c9
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00kr-0090000000-be9b911b5bceb5198ddf
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0090000000-0f188e3108f6469a5b48
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0490000000-42926fc509d963549129
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0f6x-0960000000-38ad8b94aca33eb321e0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udl-1920000000-5bbf6943424b7702e596
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-e8e44c252369ee147dfb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00ko-0190000000-28e03cc6951a989a43bb

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Benzene and substituted derivatives / Aryl chlorides / Cyclic carboximidic acids / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Alkanolamines / Organopnictogen compounds / Organooxygen compounds / Organochlorides
show 1 more
Substituents
1,4-benzodiazepine / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Cyclic carboximidic acid / Ketimine / Alkanolamine / Azacycle / Organic 1,3-dipolar compound
show 11 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, 1,4-benzodiazepinone (CHEBI:7823)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA2
Uniprot ID
P47869
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-2
Molecular Weight
51325.85 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA3
Uniprot ID
P34903
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-3
Molecular Weight
55164.055 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA4
Uniprot ID
P48169
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-4
Molecular Weight
61622.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transporter activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA5
Uniprot ID
P31644
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-5
Molecular Weight
52145.645 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRA6
Uniprot ID
Q16445
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-6
Molecular Weight
51023.69 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB1
Uniprot ID
P18505
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-1
Molecular Weight
54234.085 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB2
Uniprot ID
P47870
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-2
Molecular Weight
59149.895 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-gated chloride ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRB3
Uniprot ID
P28472
Uniprot Name
Gamma-aminobutyric acid receptor subunit beta-3
Molecular Weight
54115.04 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG1
Uniprot ID
Q8N1C3
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-1
Molecular Weight
53594.49 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRG2
Uniprot ID
P18507
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-2
Molecular Weight
54161.78 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRG3
Uniprot ID
Q99928
Uniprot Name
Gamma-aminobutyric acid receptor subunit gamma-3
Molecular Weight
54288.16 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRD
Uniprot ID
O14764
Uniprot Name
Gamma-aminobutyric acid receptor subunit delta
Molecular Weight
50707.835 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRE
Uniprot ID
P78334
Uniprot Name
Gamma-aminobutyric acid receptor subunit epsilon
Molecular Weight
57971.175 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. In the ute...
Gene Name
GABRP
Uniprot ID
O00591
Uniprot Name
Gamma-aminobutyric acid receptor subunit pi
Molecular Weight
50639.735 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-1 GABA...
Gene Name
GABRR1
Uniprot ID
P24046
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-1
Molecular Weight
55882.91 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel. Rho-2 GABA...
Gene Name
GABRR2
Uniprot ID
P28476
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-2
Molecular Weight
54150.41 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Gaba-a receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRR3
Uniprot ID
A8MPY1
Uniprot Name
Gamma-aminobutyric acid receptor subunit rho-3
Molecular Weight
54271.1 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Potentiator
General Function
Transmembrane signaling receptor activity
Specific Function
GABA, the major inhibitory neurotransmitter in the vertebrate brain, mediates neuronal inhibition by binding to the GABA/benzodiazepine receptor and opening an integral chloride channel.
Gene Name
GABRQ
Uniprot ID
Q9UN88
Uniprot Name
Gamma-aminobutyric acid receptor subunit theta
Molecular Weight
72020.875 Da
References
  1. Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
  2. Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Monooxygenase activity
Specific Function
Exhibits low testosterone 6-beta-hydroxylase activity.
Gene Name
CYP3A43
Uniprot ID
Q9HB55
Uniprot Name
Cytochrome P450 3A43
Molecular Weight
57669.21 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme displays activity toward several classes of xeno...
Gene Name
UGT2B15
Uniprot ID
P54855
Uniprot Name
UDP-glucuronosyltransferase 2B15
Molecular Weight
61035.815 Da
References
  1. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ: Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65. [PubMed:12386133]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ: Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65. [PubMed:12386133]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Court MH, Duan SX, Guillemette C, Journault K, Krishnaswamy S, Von Moltke LL, Greenblatt DJ: Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65. [PubMed:12386133]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49